Pharmafile Logo

News and Press Releases

PADCEVTM (enfortumab vedotin) in Combination with Keytruda (pembrolizumab) Receives Positive CHMP Opinion for the Treatment of Patients with Resectable Muscle-Invasive Bladder Cancer who are Ineligible for Cisplatin-Based Chemotherapy

Positive opinion is based on data from the pivotal Phase 3 EV-303 trial showing a 60% reduction in the risk of disease recurrence, progression or death and a 50% reduction...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026

Astellas
2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026

Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression  22 May 2026 -- Cambridge, UK -- STORM Therapeutics, the...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026

Storm Therapeutics
info@stormtherapeutics.com
Babraham Hall House, Babraham, Cambridge CB22 3AT

Pivotal trial data for EP0031 (A400), a next-generation Selective RET Inhibitor (SRI), in RET positive advanced NSCLC, to be presented at ASCO 2026

22 May 2026 -- London, UK -- Ellipses Pharma, a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 22, 2026

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study 21 May 2026 -- Hong Kong, Shanghai and New Jersey,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: May 21, 2026

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors Study to evaluate tertiary...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 19, 2026

Mestag Therapeutics
Suite 15 Science Village, Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL UK

Chiesi Receives MHRA Approval for Additional Dosing Regimen of Elfabrio (pegunigalsidase alfa) 2mg/kg administered every-four-weeks in adults stable with an enzyme replacement therapy

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved an additional dosing regimen of 2mg/kg administered every-four-weeks for pegunigalsidase alfa in adults stable with an enzyme replacement therapy...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 14, 2026

Chiesi
info@chiesi.uk.com
333 Styal Road Manchester M22 5LG United Kingdom

NICE recommends WINREVAIR (Sotatercept) as a treatment option for adult patients in England and Wales with pulmonary arterial hypertension (PAH)

Sotatercept is indicated for use in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III,...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2026

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

EMA Approves Updated Safety Information for Kite’s YESCARTA and TECARTUS Allow for a More Flexible Post-Infusion Management Approach

Update Enhances Convenience and Flexibility for Healthcare Professionals and Eligible Patients, while Maintaining CAR-T Safety Management Standards 24 April 2026 -- Stockley Park, UK -- Gilead and Kite Oncology today announced...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 24, 2026

Gilead Sciences, Inc

Awen Oncology secures significant new funds to advance pioneering cancer therapeutics

23 April 2026 -- Anglesey, UK -- Awen Oncology, a pioneering Wales-based therapeutics company developing next-generation cancer treatments, has secured funds from a number of sources, worth seven figures, which...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2026

Awen Oncology

Samsung Bioepis Presents Nonclinical Data for its First Novel Antibody-Drug Conjugate Candidate SBE303 at AACR 2026  

Nonclinical findings from pharmacology, pharmacokinetics, and toxicology studies support the advancement of SBE303 into clinical development with a favorable therapeutic index (TI), with its first-in-human Phase I clinical trial began...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 20, 2026

Samsung Bioepis
76, Songdogyoyuk-ro, Yeonsu-gu, Incheon

Integrated DNA Technologies Expands Coralville Manufacturing Footprint to Support Growing Global Demand for MRD Solutions

Expanded footprint delivers speed, scale and customization minimal residual disease (MRD) innovators need without compromising quality Increased production capacity leverages IDT’s highly specialized, high-throughput manufacturing platform. 20 April 2026 --...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 20, 2026

Integrated DNA Technologies (IDT)
custcare@idtdna.com

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Agreement will enable selection of Kahimmune’s first companion neoantigen therapy candidate against colorectal cancer and pancreatic cancer, with financial support from Bpifrance   Kahimmune exploits dark genome to develop next-generation...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 18, 2026

Kahimmune Therapeutics
contact@kahimmune.com
2 Avenue Du Blanchissage, 84000 Avignon, France

Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026 

Asgard’s immunotherapy, AT-108, induces systemic, dose-dependent efficacy with broad tumor activity in preclinical studies and key biomarkers identified AT-108 combines the advantages of an off-the-shelf gene therapy whilst offering a...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2026

Asgard Therapeutics
info@asgardthx.com
Medicon Village, 223 81 Lund, Sweden

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2026

Storm Therapeutics
info@stormtherapeutics.com
Babraham Hall House, Babraham, Cambridge CB22 3AT

Oncodesign Services extends collaboration with GIP ARRONAX to strengthen astatine-211 supply for targeted alpha radiotherapy

13 April 2026 -- Dijon, France -- Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 13, 2026

Oncodesign Services
contact@oncodesign-services.com
20 Rue Jean Mazen 21 000 Dijon France